Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is a leading multinational healthcare company that has a strong focus on providing personalized diagnosis and treatment of cancer through its proprietary genomic and molecular technologies. Despite recent challenges related to recoupment of previous payments and discontinuation of one of its tests, the company's core business is expected to continue growing at a steady pace with the potential for new partnerships and acquisitions. Additionally, the company's strong pipeline and focus on high-growth areas in the medical and life science tools sector make it a strong long-term investment opportunity.

Bears say

MDxHealth is facing challenges due to the discontinuation of sales for their Resolve UTI test, lowering their 2026 revenue guide and missing Q1 revenue and earnings expectations. This will require MDxHealth to rely on alternative growth drivers such as their ExoDx test and increased productivity from sales reps. The company has a low- to mid-teens revenue growth potential with expanding margins, but their recent financials raise concern and may require better execution from management for long-term success.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.